Last Updated: May 12, 2026

Suppliers and packagers for telmisartan


✉ Email this page to a colleague

« Back to Dashboard


telmisartan

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Alembic TELMISARTAN telmisartan TABLET;ORAL 202130 ANDA Alembic Pharmaceuticals Limited 46708-608-10 100 TABLET in 1 CARTON (46708-608-10) 2016-06-25
Alembic TELMISARTAN telmisartan TABLET;ORAL 202130 ANDA Alembic Pharmaceuticals Limited 46708-608-30 30 TABLET in 1 BOTTLE (46708-608-30) 2016-06-25
Alembic TELMISARTAN telmisartan TABLET;ORAL 202130 ANDA Alembic Pharmaceuticals Limited 46708-608-91 1000 TABLET in 1 BOTTLE (46708-608-91) 2016-06-25
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for telmisartan

Last updated: April 26, 2026

Who Supplies Telmisartan API and Finished-Dose Products?

What companies supply telmisartan API?

Global telmisartan supply is split between (1) API manufacturers and (2) API “brand owners” that package telmisartan into branded or generic products through contract manufacturing. The API market is concentrated in Asia, with commercial scale plants in India and China and select specialized supply in other regions.

Representative telmisartan API suppliers (manufacturers) Supplier Country What they typically supply Notes
Zhejiang Huahai Pharmaceutical Co., Ltd. China Telmisartan API Large-scale cardiovascular API supplier; common in global generic supply chains.
Aarti Pharmalabs / Aarti Industries (Aarti Group companies) India Telmisartan API Cardiovascular focused API supplier; supplies multiple generic dossiers.
Micro Labs / Micro Labs API footprint India Telmisartan API (through group manufacturing network) Often supplies the active in finished-dose pipelines via its manufacturing ecosystem.
Hetero Drugs Ltd. India Telmisartan API Broad generic and cardiovascular portfolio via integrated manufacturing.
Macleods Pharmaceuticals / API network India Telmisartan API (via contract and group supply) Supplies telmisartan into tablets through generic channels.
Dr. Reddy’s Laboratories (active pharma manufacturing) India Telmisartan (API and intermediates within broader portfolio) Supplies API/intermediates for downstream operations; also participates in global generic supply.
Zydus Lifesciences India Telmisartan-related API supply Cardiovascular API capacity in India feeding finished-dose manufacturing.

Practical procurement implication: telmisartan is widely stocked by multiple API suppliers because it has long been off-patent in most jurisdictions and competes largely on dossier readiness, cost, and compliance.

What companies supply telmisartan finished-dose tablets?

Finished-dose telmisartan is supplied by many generic manufacturers worldwide. Procurement and sourcing typically rely on tender-ready WHO/EMA/FDA-compliant products, depending on destination market.

Representative telmisartan tablet suppliers (finished dose) Company Country Common telmisartan strengths Typical market role
Teva Israel/US footprint 20 mg, 40 mg, 80 mg Major global generic supplier.
Sandoz Switzerland 20 mg, 40 mg, 80 mg Large generics and biosimilars group with telmisartan in portfolio.
Mylan/Viatris US/Global 20 mg, 40 mg, 80 mg Broad generic cardiovascular coverage.
Zydus India 20 mg, 40 mg, 80 mg India-origin generic supplier for export markets.
Sun Pharma India 20 mg, 40 mg, 80 mg Global generic cardiovascular portfolio.
Dr. Reddy’s India 20 mg, 40 mg, 80 mg International generics and in-country brands.
Hikma UK/Jordan 20 mg, 40 mg, 80 mg Strong in EU and emerging markets generics.
Aurobindo India 20 mg, 40 mg, 80 mg Common generic supplier for ARB tablets.

Procurement implication: finished-dose supply depends on local registration and the specific salt form used (telmisartan is typically provided as telmisartan in tablets, with excipient systems differing by manufacturer).


How do suppliers qualify for telmisartan procurement?

What documentation and quality controls matter most?

Telmisartan procurement typically hinges on regulatory and quality readiness rather than novelty. For buyers, qualification usually includes:

  • Regulatory status of the product (destination-market approved product dossiers).
  • API compliance: DMF/CEP availability where applicable; CoA and batch release documentation.
  • GMP compliance: inspection status of the API plant and finished-dose plant.
  • Analytical package strength: impurity profile control, polymorph control where relevant, and validated HPLC/GC methods.
  • Stability commitment: real-time and accelerated stability data for the marketed shelf-life.

Key buyer reality for telmisartan: the drug has mature manufacturing routes and broad supplier coverage, so differentiation comes from compliance track record, release reliability, and cost-to-supply stability.


Which supply chain structure dominates telmisartan sourcing?

Is supply typically direct API, or contract manufacturing?

For telmisartan, both models are common:

  1. Direct API purchase → internal formulation/packaging

    • Buyers contract finished-dose manufacturing or do it in-house.
    • Requires full control of formulation change, validation, and packaging specs.
  2. API purchase → outsourced finished-dose manufacturing

    • Buyers sign contract manufacturing agreements for tablet manufacturing, packaging, and batch release.
    • Requires tight change-control and specification alignment.
  3. Finished-dose sourcing directly

    • Buyers place tenders for registered finished tablets.
    • Lower technical overhead, higher emphasis on regulatory documentation and market authorization.

Market signals: why telmisartan has many suppliers

Telmisartan is a mature ARB with global generic competition. Supply density is driven by:

  • Long commercialization history across EU, US, and emerging markets.
  • Off-patent status in most major jurisdictions for years.
  • Multiple established API synthesis routes that scale economically.
  • Established impurity control approaches used by numerous manufacturers.

Key Takeaways

  • Telmisartan supply is highly fragmented but heavily concentrated in Asia, with multiple established API and finished-dose suppliers.
  • Procurement is won on regulatory readiness, GMP history, and analytical package control, not on innovation.
  • Buyers can source telmisartan through direct API-to-formulation, API plus contract manufacturing, or direct finished-dose tendering.

FAQs

Which countries are the main telmisartan API sources?

India and China dominate telmisartan API supply, with a secondary role for other regions that support specific dossier or contract manufacturing needs.

Do telmisartan suppliers offer multiple tablet strengths?

Most major generic suppliers offer telmisartan tablets commonly in 20 mg, 40 mg, and 80 mg, depending on registration in the destination market.

Is telmisartan API exchangeable across suppliers?

Not by default. While telmisartan is the same active, exchange requires qualification of the API grade, impurity profile, polymorph behavior (where applicable), and compatibility with the formulation.

What matters most for tenders: API or finished-dose?

It depends on the buyer model. Many tenders favor finished-dose compliance because it reduces technical qualification and shortens time-to-supply.

How do buyers reduce supply disruption risk?

Use dual-sourcing (two qualified API or two qualified finished-dose sources), lock quality agreements, and enforce strict specification and change-control clauses.


References

[1] European Medicines Agency (EMA), European public assessment reports and product information. (Accessed via EMA public databases). https://www.ema.europa.eu/
[2] FDA, Drugs@FDA database (for telmisartan and telmisartan-containing products). https://www.accessdata.fda.gov/scripts/cder/daf/
[3] WHO, WHO Prequalification Programme (product listings for telmisartan when applicable). https://extranet.who.int/pqweb/
[4] USP, Compendial information for telmisartan substance and product standards where applicable. https://www.uspnf.com/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.